NeoDoppler: New Ultrasound Technology for Continuous Monitoring of Cerebral Circulation Pilot

Key facts

Sponsor

St. Olavs Hospital

Principal Investigator

Siri Ann Nyrnes, MD, PhD, MD

Childrens Clinic, St. Olavs University Hospital and NTNU

Intervention

NeoDoppler - CE certified(device)

Enrollment

180 enrolled

Eligibility

All sexes

Timeline

2024 – 2029

Study locations (1)

• Children's clinic, St. Olavs University Hospital, Trondheim, Norway

Collaborators

Norwegian University of Science and Technology

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Arterial duct anomaly

Additional recruiting or active studies for the same condition.

• ACTIVE NOT RECRUITINGNCT06950164
  Dynamic Changes of Ductus Arteriosus in < 31 Weeks Preterm Infants: an Observational Study
  Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
• RECRUITINGNCT06658496
  PDA for Kidneys Study
  University of Wisconsin, Madison
• RECRUITINGPHASE2NCT07143201
  Precision Dosing of Oral Ibuprofen for PDA, A Pilot RCT
  Hamilton Health Sciences Corporation
• RECRUITINGNCT05264753
  Post Marketing Clinical Follow Up Study to Evaluate Efficacy and Safety of the Occlutech PDA Occluder in Patients With Patent Ductus Arteriosus Defects
  Occlutech International AB
• ACTIVE NOT RECRUITINGNCT04371081
  Amplatzer Piccolo Occluder Japan Post-marketing Database Surveillance
  Abbott Medical Devices
• ENROLLING BY INVITATIONNANCT04667455
  Improving Care for Children With Congenital Heart Disease.
  Lund University Hospital
• ACTIVE NOT RECRUITINGNCT03782610
  Early Prediction of Spontaneous Patent Ductus Arteriosus (PDA) Closure and PDA-Associated Outcomes
  Nationwide Children's Hospital
• ACTIVE NOT RECRUITINGPHASE3NCT03456336
  Management of the PDA Trial
  NICHD Neonatal Research Network

See all trials for Arterial duct anomaly →